TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

TPEX:4157 Revenue

TaiGen Biopharmaceuticals Holdings had revenue of 10.34M TWD in the quarter ending March 31, 2026, a decrease of -4.96%. This brings the company's revenue in the last twelve months to 258.93M, up 70.95% year-over-year. In the year 2025, TaiGen Biopharmaceuticals Holdings had annual revenue of 259.47M with 72.24% growth.

• Revenue (ttm): 258.93M
• Revenue Growth: +70.95%
• P/S Ratio: 24.91
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 6.45B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	259.47M	108.82M	72.24%
Dec 31, 2024	150.65M	27.52M	22.35%
Dec 31, 2023	123.13M	86.90M	239.87%
Dec 31, 2022	36.23M	-1.26B	-97.20%
Dec 31, 2021	1.29B	1.27B	5,426.95%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 30, 2026

Data Sources Report a data error